The apparent antipsychotic action of the 5-HT2a receptor antagonist M100907 in a mouse model of schizophrenia is counteracted by ritanserin

This publication has 13 references indexed in Scilit:

• Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile.
  1996
• The selective 5-HT2a receptor antagonist MDL 100,907 counteracts the psychomotor stimulation ensuing manipulations with monoaminergic, glutamatergic or muscarinic neurotransmission in the mouse ? implications for psychosis
  Journal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1995
• 5-HT2 receptor subtypes: A family re-united?
  Trends in Pharmacological Sciences, 1995
• Evidence for biochemical heterogeneity in schizophrenia: a multivariate study of monoaminergic indices in human post-mortal brain tissue
  Journal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1994
• Ritanserin, a Selective 5-HT_2/1CAntagonist, and Negative Symptoms in Schizophrenia
  The British Journal of Psychiatry, 1993
• Alterations in Extracellular and Tissue Levels of Biogenic Amines in Rat Brain Induced by the Serotonin₂Receptor Antagonist, Ritanserin
  Journal of Neurochemistry, 1992
• Gaps and peculiarities in 5-HT2 receptor studies.
  1990
• The concept of selectivity in 5-HT receptor research
  European Journal of Pharmacology: Molecular Pharmacology, 1990
• The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist.
  Proceedings of the National Academy of Sciences, 1986
• RECEPTOR-BINDING PROPERTIES INVITRO AND INVIVO OF RITANSERIN - A VERY POTENT AND LONG-ACTING SEROTONIN-S-2 ANTAGONIST
  1985